Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin (Laser Genesis)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The objective of this study is to examine the ability of dermal rejuvenation therapies to protect geriatric skin from ultraviolet light (UVB)-induced carcinogenesis. Skin cancers (including basal cell carcinoma and squamous cell carcinoma) are the most common types of malignancy and are related to UVB exposure in sunlight. UVB-irradiation of skin causes specific DNA damage to keratinocytes that can lead to cancer-causing mutations if they are allowed to persist in proliferating cells. Moreover, the incidence of skin cancers is much greater in elderly over younger individuals. The objective of the present study is to build upon our previous data and test the effect of a non ablative Nd:YAG laser (LaserGenesis) of a localized area of skin on dermal IGF-1 production and UVB-mediated keratinocyte effects. Treatment of skin using a non ablative high-peak power microsecond pulsed 1064 nm Nd:YAG laser (Cutera's LaserGenesisTM laser) leads to papillary dermal heating. The laser targets the microvasculature and stimulates collagen production while protecting the epidermis. Generally, Laser Genesis is used clinically to improve irregularities in the contour, texture, and color of the skin. Laser Genesis is also used to help treat photoaging by increasing collagen formation, suggesting that it stimulates fibroblast activity and thus possibly increases levels of protective IGF-1.
Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers [ Time Frame: untreated and LaserGenesis treated, three months after treatment, 24 hours after 350 J/m2 of UVB ]
Number of double positive cells per 1000 total basal layer keratinocytes
Secondary Outcome Measures :
Relative Level of IGF-1 mRNA in the Skin [ Time Frame: untreated and LaserGenesis treated, three months after treatment ]
IGF-1 mRNA per 100,000 beta-2 microglobulin mRNA. Beta-2 microglobulin mRNA was used as a reference gene for this assessment and that the data represent number of copies IGF-1/100,000 copies b2-microglobulin.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
65 Years to 99 Years (Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Only subjects older than 65 years will be enrolled.
Subject's skin type must be "Fair", Fitzpatrick type I or II.
Subjects who have underlying diseases that could affect wound healing (eg, diabetes mellitus)
on medications that are known photosensitizers,
or have a history of abnormal scarring (eg, keloids) will be excluded.
Subjects will be asked the screening questions below as part of the inclusion/exclusion criteria
How old are you?
Do you regularly use tanning beds?
Are you being treated with light therapy?
Have you had any diseases that got worse when you went in the sun?
Are you taking any medications that warn you to stay out of the sun?
Have you ever had a reaction to medications that were applied to your skin?
When cuts or wounds on your skin heal, are the scars abnormally large or take a long time to heal?
Do you have diabetes mellitus or have you ever had high blood sugar?